In brief: Sirtex, Imugene, Biosignal, Uscom
Monday, 08 November, 2004
Cancer technology specialist Sirtex (ASX:SRX) has firmed new distribution deals in Israel and India for its targeted radioactive particle liver cancer treatment, SIR-Spheres, which has recently won regulatory approval in both markets.
The company has also named a distributor for Hong Kong and China, where it has won regulatory approval to conduct clinical trials. Sirtex said it regarded the Indian and Chinese markets as small in comparison with its North American and European opportunities, because of the high cost of the treatment.
Imugene
Paul MacLernan has moved from his position as head of Agenix' global health business to become Imugene's (ASX:IMU) chief operating officer.
MacLernan restructured Agenix' animal health business, and brought in increased sales with new distributor agreements - the right touch, Imugene said, for its business as it began to roll out its receptor mimic technology and adenoviral vector delivery system around the world.
Imugene also appointed Dr Peter Claxton as regulatory affairs consultant.
Biosignal
Biosignal (ASX:BOS) has engaged Boston firm PureTech Development to help it find partners to develop and market its anti-bacterial furanone technology for pharmaceuticals, medical devices and implant applications in the US.
Uscom
Uscom (ASX:UCM) has won regulatory approval in Japan for its cardiac output devices. CEO Gary Davey said approval in Japan, the world's second-biggest market for medical devices, came two months ahead of schedule.
Oxytocin analogue treats chronic abdominal pain
Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
